Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock [Yahoo! Finance]
Acrivon Therapeutics, Inc. (ACRV)
Company Research
Source: Yahoo! Finance
Acrivon Therapeutics achieved statistically significant prospective validation of its AP3 patient selection approach via its ACR-368 OncoSignature assay. This assay demonstrated an ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy. Its lead pipeline candidate, ACR-368/prexasertib, a CHK1/2 inhibitor, is being developed in phase II studies across multiple tumor types. In April, the company reported initial positive clinical data from a phase II study of ACR-368 for patients with locally advanced or metastatic, recurrent platinum-resistant ovarian cancer or endometrial adenocarcinoma. The study demonstrated an initial combined overall confirmed response rate of 50%, exceeding the clinical bar, which the company thinks is required to improve over standard of care. Acrivon Therapeutics' stock has risen 61.6% year to date against a decrease of 9.3% for the industry. Image Source: Zacks Investment Research Another candidate, ACR-2316, a WEE1/PKMY
Show less
Read more
Impact Snapshot
Event Time:
ACRV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRV alerts
High impacting Acrivon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRV
News
- Mirum (MIRM) Soars on Interim Data From Liver Disease Studies [Yahoo! Finance]Yahoo! Finance
- SAGE's Huntington's Disease Study Meets Primary Endpoint [Yahoo! Finance]Yahoo! Finance
- Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Acrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswire
- Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
ACRV
Earnings
- 5/14/24 - Beat
ACRV
Sec Filings
- 5/21/24 - Form 4
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- ACRV's page on the SEC website